Emerging multidrug-resistant candida duobushaemulonii infections in Panama hospitals: Importance of laboratory surveillance and accurate identification

Journal of Clinical Microbiology

Volumn 56, Issue 7, 2018, Pages

  Ramos, Ruben ^a   Caceres, Diego H ^b,c   Perez, Marilyn ^a   Garcia, Nicole ^a   Castillo, Wendy ^a   Santiago, Erika ^d   Borace, Jovanna ^d   Lockhart, Shawn R ^b   Berkow, Elizabeth L ^b   Hayer, Lizbeth ^e   Espinosa Bode, Andres ^b   Moreno, Jose ^a   Jackson, Brendan R ^b   Moran, Jackeline ^a   Chiller, Tom ^b   De Villarreal, Gloriela ^a   Sosa, Nestor ^a   Vallabhaneni, Snigdha ^b  

^a Instituto Conmemorativo Gorgas de Estudios de la Salud   (Panama)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c OAK RIDGE INSTITUTE FOR SCIENCE AND EDUCATION   (United States)

^d Santo Tomas Hospital   (Panama)

^e Instituto Conmemorativo Gorgas de Estudios de la Salud   (Panama)

Author keywords

Candida duobushaemulonii; Emerging yeast; Invasive candidiasis; Laboratory surveillance; Multidrug resistance

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; MICAFUNGIN; VORICONAZOLE; ANTIFUNGAL AGENT;

ADOLESCENT; AGED; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BLOODSTREAM INFECTION; CANDIDA; CANDIDA DUOBUSHAEMULONII; CANDIDA DUOBUSHAEMULONII INFECTION; CANDIDIASIS; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FEMALE; FUNGUS IDENTIFICATION; FUNGUS ISOLATION; HUMAN; LABORATORY TEST; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PANAMA; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; CANDIDEMIA; CLASSIFICATION; DRUG EFFECT; EPIDEMIOLOGICAL MONITORING; EPIDEMIOLOGY; ISOLATION AND PURIFICATION; MATRIX-ASSISTED LASER DESORPTION-IONIZATION MASS SPECTROMETRY; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDEMIA; CANDIDIASIS; DRUG RESISTANCE, MULTIPLE, FUNGAL; EPIDEMIOLOGICAL MONITORING; MICROBIAL SENSITIVITY TESTS; PANAMA; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 85049174221     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.00371-18     Document Type: Article

References (23)

1. Cendejas-Bueno E, Kolecka A, Alastruey-Izquierdo A, Theelen B, Groenewald M, Kostrzewa M, Cuenca-Estrella M, Gómez-López A, Boekhout T. 2012. Reclassification of the Candida haemulonii complex as Candida haemulonii (C. Haemulonii group I), C. Duobushaemulonii sp. Nov. (C. Haemulonii group II), and C. Haemulonii var. Vulnera var. Nov.: three multiresistant human pathogenic yeasts. J Clin Microbiol 50:3641-3651. Https://doi.org/10.1128/JCM.02248-12.
2. Chowdhary A, Sharma C, Meis JF. 2017. Candida auris: A rapidly emerging cause of hospital-acquired multidrug-resistant fungal infections globally. PLoS Pathog 13:e1006290. Https://doi.org/10.1371/journal.ppat.1006290.
3. Lockhart SR, Etienne KA, Vallabhaneni S, Farooqi J, Chowdhary A, Govender Colombo NP AL, Calvo B, Cuomo CA, Desjardins CA, Berkow EL, Castanheira M, Magobo RE, Jabeen K, Asghar RJ, Meis JF, Jackson B, Chiller T, Litvintseva AP. 2017. Simultaneous emergence of multidrugresistant Candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological Analyses. Clin Infect Dis 64:134-140. Https://doi.org/10.1093/cid/ciw691.
4. Kathuria S, Singh PK, Sharma C, Prakash A, Masih A, Kumar A, Meis JF, Chowdhary A. 2015. Multidrug-resistant Candida auris misidentified as Candida haemulonii: characterization by matrix-assisted laser desorption ionization-time of flight mass spectrometry and DNA sequencing and its antifungal susceptibility profile variability by Vitek 2, CLSI broth microdilution, and Etest method. J Clin Microbiol 53:1823-1830. Https://doi.org/10.1128/JCM.00367-15.
5. Hou X, Xiao M, Chen SC, Wang H, Cheng JW, Chen XX, Xu ZP, Fan X, Kong F, Xu YC. 2016. Identification and antifungal susceptibility profiles of Candida haemulonii species complex clinical isolates from a multicenter study in China. J Clin Microbiol 54:2676-2680. Https://doi.org/10 .1128/JCM.01492-16.
6. Ramos LS, Figueiredo-Carvalho MH, Barbedo LS, Ziccardi M, Chaves AL, Zancopé-Oliveira RM, Pinto MR, Sgarbi DB, Dornelas-Ribeiro M, Branquinha MH, Santos AL. 2015. Candida haemulonii complex: species identification and antifungal susceptibility profiles of clinical isolates from Brazil. J Antimicrob Chemother 70:111-115. Https://doi.org/10 .1093/jac/dku321.
7. Kumar A, Prakash A, Singh A, Kumar H, Hagen F, Meis JF, Chowdhary A2. 2016. Candida haemulonii species complex: an emerging species in India and its genetic diversity assessed with multilocus sequence and amplified fragment-length polymorphism analyses. Emerg Microbes Infect 5:e49. Https://doi.org/10.1038/emi.2016.49.
8. Boatto HF, Cavalcanti SD, Del Negro GM, Girão MJ, Francisco EC, Ishida K, Gompertz OF. 2016. Candida duobushaemulonii: an emerging rare pathogenic yeast isolated from recurrent vulvovaginal candidiasis in Brazil. Mem Inst Oswaldo Cruz 111:407-410. Https://doi.org/10.1590/0074-02760160166.
9. Fang SY, Wei KC, Chen WC, Lee SJ, Yang KC, Wu CS, Sun PL7. 2016. Primary deep cutaneous candidiasis caused by Candida duobushaemulonii in a 68-year-old man: the first case report and literature review. Mycoses 59:818-821. Https://doi.org/10.1111/myc.12540.
10. de Almeida JN, Jr., Assy JG, Levin AS, Del Negro GM, Giudice MC, Tringoni MP, Thomaz DY, Motta AL, Abdala E, Pierroti LC, Strabelli T, Munhoz AL, Rossi F, Benard G. 2016. Candida haemulonii complex species, Brazil, January 2010-March 2015. Emerg Infect Dis 22:561-563. Https://doi.org/10.3201/eid2203.151610.
11. Araúz AB, Caceres DH, Santiago E, Armstrong P, Arosemena S, Ramos C, Espinosa-Bode A, Borace J, Hayer L, Cedeño I, Jackson BR, Sosa N, Berkow EL, Lockhart SR, Rodriguez-French A, Chiller T. 2018. Isolation of Candida auris from 9 patients in Central America: importance of accurate diagnosis and susceptibility testing. Mycoses 61:44-47. Https://doi.org/10.1111/myc.12709.
12. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard, 3rd ed. CLSI document M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
13. Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, Reboli AC, Schuster MG, Vazquez JA, Walsh TJ, Zaoutis TE, Sobel JD. 2016. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 62:e1-e50. Https://doi.org/10.1093/cid/civ1194.
14. Pinhati HM, Casulari LA, Souza AC, Siqueira RA, Damasceno CM, Colombo AL. 2016. Outbreak of candidemia caused by fluconazole resistant Candida parapsilosis strains in an intensive care unit. BMC Infect Dis 16:433. Https://doi.org/10.1186/s12879-016-1767-9.
15. Guo W, Gu HF, Zhang HG, Chen SB, Wang JQ, Geng SX, Li L, Liu P, Liu X, Ji YR, Li SW, Yang L. 2015. An outbreak of Candida parapsilosis fungemia among preterm infants. Genet Mol Res 14:18259-18267. Https://doi.org/10.4238/2015.December.23.13.
16. da Silva Ruiz L, Montelli AC, Sugizaki Mde F, Da Silva EG, De Batista GC, Moreira D, Paula CR. 2013. Outbreak of fungemia caused by Candida parapsilosis in a neonatal intensive care unit: molecular investigation through microsatellite analysis. Rev Iberoam Micol 30:112-115. Https://doi.org/10.1016/j.riam.2012.10.003.
17. Hernández-Castro R, Arroyo-Escalante S, Carrillo-Casas EM, Moncada-Barrón D, Alvarez-Verona E, Hernández-Delgado L, Torres-Narváez P, Lavalle-Villalobos A. 2010. Outbreak of Candida parapsilosis in a neonatal intensive care unit: a health care workers source. Eur J Pediatr 169: 783-787. Https://doi.org/10.1007/s00431-009-1109-7.
18. Pan American Health Organization, World Health Organization. 3 October 2016. Epidemiological alert: Candida auris outbreaks in health care services. Http://www.paho.org/hq/index.php?option-com-docman& task-doc-view&Itemid-270&gid-36353.
19. CDC. June 2016. Clinical alert to U.S. Healthcare facilities-June 2016. Global emergence of invasive infections caused by the multidrugresistant yeast Candida auris. CDC, Atlanta, GA. Https://www.cdc.gov/fungal/diseases/candidiasis/candida-auris-alert.html.
20. European Centre for Disease Prevention and Control. 2016. Candida auris in healthcare settings-Europe. European Centre for Disease Prevention and Control, Stockholm, Sweden. Http://ecdc.europa.eu/en/publications/Publications/Candida-in-healthcare-settings-19-Dec-2016 .pdf.
21. Ben-Ami R, Berman J, Novikov A, Bash E, Shachor-Meyouhas Y, Zakin S, Maor Y, Tarabia J, Schechner V, Adler A, Finn T. 2017. Multidrug-resistant Candida haemulonii and C. Auris, Tel Aviv, Israel. Emerg Infect Dis 23: 195-203. Https://doi.org/10.3201/eid2302.161486.
22. Tsay S, Kallen A, Jackson BR, Chiller TM, Vallabhaneni S. 2018. Approach to the investigation and management of patients with Candida auris, an emerging multidrug-resistant yeast. Clin Infect Dis 66:306-311. Https://doi.org/10.1093/cid/cix744.
23. Lockhart SR, Jackson BR, Vallabhaneni S, Ostrosky-Zeichner L, Pappas PG, Chiller T. 2017. Thinking beyond the common Candida species: need for species-level identification of Candida due to the emergence of multidrugresistant Candida auris. J Clin Microbiol 55:3324-3327. Https://doi.org/10 .1128/JCM.01355-17.